4D Molecular Therapeutics Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific
Reuters
Oct 31, 2025
<a href="https://laohu8.com/S/FDMT">4D Molecular Therapeutics</a> Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific
4D Molecular Therapeutics Inc. (4DMT) announced an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the Asia-Pacific region, including Japan. Under the terms of the agreement, 4DMT will receive an upfront cash payment of $85 million and is expected to receive at least $50 million in cost sharing from Otsuka over the next three years to support global development activities. The agreement also includes up to $336 million in potential regulatory and commercial milestone payments, along with tiered double-digit royalties based on net sales in Otsuka's territories. 4DMT retains full development and commercialization rights for 4D-150 outside the APAC region, including the U.S., Latin America, and Europe. Proceeds and cost sharing from this agreement are expected to support a global Phase 3 clinical trial in diabetic macular edema (DME) and pre-commercial activities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566023-en) on October 31, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.